Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8+ T cell responses

不依赖于中和抗体的SARS-CoV-2控制与鼻内疫苗诱导的CD8+ T细胞反应相关

阅读:2
作者:Hiroshi Ishii,Takushi Nomura,Hiroyuki Yamamoto,Masako Nishizawa,Trang Thi Thu Hau,Shigeyoshi Harada,Sayuri Seki,Midori Nakamura-Hoshi,Midori Okazaki,Sachie Daigen,Ai Kawana-Tachikawa ,Noriyo Nagata,Naoko Iwata-Yoshikawa,Nozomi Shiwa,Tadaki Suzuki,Eun-Sil Park,Maeda Ken,Taishi Onodera,Yoshimasa Takahashi,Kohji Kusano,Ryutaro Shimazaki,Yuriko Suzaki,Yasushi Ami,Tetsuro Matano

Abstract

Effective vaccines are essential for the control of the coronavirus disease 2019 (COVID-19) pandemic. Currently developed vaccines inducing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S)-antigen-specific neutralizing antibodies (NAbs) are effective, but the appearance of NAb-resistant S variant viruses is of great concern. A vaccine inducing S-independent or NAb-independent SARS-CoV-2 control may contribute to containment of these variants. Here, we investigate the efficacy of an intranasal vaccine expressing viral non-S antigens against intranasal SARS-CoV-2 challenge in cynomolgus macaques. Seven vaccinated macaques exhibit significantly reduced viral load in nasopharyngeal swabs on day 2 post-challenge compared with nine unvaccinated controls. The viral control in the absence of SARS-CoV-2-specific NAbs is significantly correlated with vaccine-induced, viral-antigen-specific CD8+ T cell responses. Our results indicate that CD8+ T cell induction by intranasal vaccination can result in NAb-independent control of SARS-CoV-2 infection, highlighting a potential of vaccine-induced CD8+ T cell responses to contribute to COVID-19 containment.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。